LB Pharmaceuticals Inc (LBRX)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
LBRX Reports $126.5M Cash for LB-102 Phase 3 Schizophrenia Trial
# 🧾 What This Document Is This is LB Pharmaceuticals' **Annual Report to Shareholders (ARS)**. Think of it as the company's yearly "report card" sent directly to its owners. It's a comprehensive but more reader-friendly summary of their performance, strategy, and financial health compared to a dens
SEC filings
All filings →Insider trades
All insider trades →LB Pharmaceuticals Inc has no reported insider trades in the last 90 days.